ResearcherAcobiom (France)Active in the last 2 years
David Piquemal
Matched on ORCID iD 0000-0002-5870-4276; OpenAlex author ID A5065614520. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 5
- €2.7 billion for the treatment of patients with pancreatic cancer: an overview and perspectives in France. Co-author DOI 10.1016/j.clinre.2026.102873↗
- Nationwide trends over 10 years in epidemiology and management of pancreatic ductal adenocarcinoma: A real-world study from the French administrative database. Co-author DOI 10.1016/j.clinre.2024.102426↗
- Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. Co-author DOI 10.21037/jgo-22-946↗
- Predictive Values of Blood-Based RNA Signatures for the Gemcitabine Response in Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers12113204↗
- A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv133↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jean‐Baptiste Bachet · 3 shared papers, 2023–2026 · strength 0.74
- Paper €2.7 billion for the treatment of patients with pancreatic cancer: an overview and perspectives in France. DOI 10.1016/j.clinre.2026.102873↗
- Paper Nationwide trends over 10 years in epidemiology and management of pancreatic ductal adenocarcinoma: A real-world study … DOI 10.1016/j.clinre.2024.102426↗
- Paper Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma. DOI 10.21037/jgo-22-946↗
- Léo Mas · 2 shared papers, 2024–2026 · strength 0.61
- Paper €2.7 billion for the treatment of patients with pancreatic cancer: an overview and perspectives in France. DOI 10.1016/j.clinre.2026.102873↗
- Paper Nationwide trends over 10 years in epidemiology and management of pancreatic ductal adenocarcinoma: A real-world study … DOI 10.1016/j.clinre.2024.102426↗
- Honorat Agbeci · 1 shared paper, 2026 · strength 0.36
- Jerome F. Cros · 2 shared papers, 2020–2023 · strength 0.27
- Sylvain Manfrédi · 1 shared paper, 2023 · strength 0.12
- Côme Lepage · 1 shared paper, 2023 · strength 0.12
- Noelle K. LoConte · 1 shared paper, 2023 · strength 0.12
- Christophe Tournigand · 1 shared paper, 2023 · strength 0.12
- Emmanuelle Kempf · 1 shared paper, 2023 · strength 0.12
- Émilie Soularue · 1 shared paper, 2023 · strength 0.12
- Cindy Canivet · 1 shared paper, 2023 · strength 0.12
- Isabelle Trouilloud · 1 shared paper, 2023 · strength 0.12
- Antoine Drouillard · 1 shared paper, 2023 · strength 0.12
- François Ghiringhelli · 1 shared paper, 2023 · strength 0.12
- Barbara Bournet · 1 shared paper, 2023 · strength 0.12
- G. Deplanque · 1 shared paper, 2015 · strength 0.04
- Bohuslav Melichar · 1 shared paper, 2015 · strength 0.04
- Mohamed Hebbar · 1 shared paper, 2015 · strength 0.04
- Pascal R. Hammel · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.